Kenneth Saag, MD, explores the clinical significance of a study demonstrating treatment with pegloticase leads to bone remodeling in patients with gout.
https://www.hcplive.com/view/pegloticase-treatment-linked-to-concomitant-bone-remodeling-in-gout
A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.
https://www.hcplive.com/view/rgx-314-gene-therapy-namd-well-tolerated-phase-1-2a-study
In this episode, all things AID from the 17th annual ATTD, including updates from Insulet Corporation and Omnipod, study data from the Control IQ algorithm, the SMASH study, and a peak into the f...
https://www.hcplive.com/view/diabetes-dialogue-all-things-aid-at-attd-2024
The investigators seek to replicate the data in a future randomized control trial, and they hope to compare biofeedback to different therapies such as pulmonary rehabilitation.
In part 5 of our 5-part discussion, experts discuss their perspective on appropriate guidance for screening age and the future of CRC advocacy.
In part 4 of our 5-part discussion, experts discuss how to navigate conversations about risk factors and symptoms surrounding CRC.
https://www.hcplive.com/view/navigating-patient-histories-risk-factor-conversations-in-crc-screening
In part 3 of our 5-part discussion, experts discuss the importance of screening among younger patient populations and strategies to encourage screening in patient populations susceptible to nonad...
https://www.hcplive.com/view/reaching-patients-in-need-of-screening-for-colorectal-cancer
In part 2 of our 5-part discussion, experts discuss challenges they face getting patients to engage in screening and how to effectively discuss screening with patients.
https://www.hcplive.com/view/pressing-challenges-in-colorectal-cancer-screening
In part 1 of our 5-part discussion, experts discuss recent screening recommendation updates and the advent of new screening modalities.
https://www.hcplive.com/view/updates-in-colorectal-cancer-screening-recommendations
The recent rise in colorectal cancer incidence and mortality in younger patients has sparked a serious discussion about strategies to increase screening uptake and adherence, raising questions ab...
Qazi discusses the impact of having standardized definitions and treatment approaches for pouchitis and inflammatory conditions of the pouch.
The first quarterly issue of 2024 reviews a promising JAK inhibitor for acute severe ulcerative colitis, fenofibrates in PBC, new recommendations from the AGA, and a next generation multi-target ...
Recent recommendations from the AGA may help gastroenterologists manage the rising rate of pouchitis with the aid of clinical evidence.
Qazi discusses a review of the use of fenofibrate as a first-line therapy in treatment-naive patients with PBC and its implications for biochemical response.
https://www.hcplive.com/view/taha-qazi-md-fenofibrate-first-line-therapy-primary-biliary-cholangitis
Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.
https://www.hcplive.com/view/managing-patients-with-high-risk-pdr-and-dme
Topline results at week 52 show LPCN 1148 treatment met both the primary and hepatic encephalopathy endpoints in the management of cirrhosis.
https://www.hcplive.com/view/lpcn-1148-achieves-phase-2-endpoints-cirrhosis-management
New data suggest adding fibrate therapy to frontline PBC treatment could result in earlier and higher rates of biochemical response.
https://www.hcplive.com/view/fenofibrates-treatment-primary-biliary-cholangitis
An expert retina specialist discusses challenges faced by DME patients showing suboptimal response to standard anti-VEGF treatment, emphasizing the need to reduce injection burden while preventin...
https://www.hcplive.com/view/managing-dme-patients-unresponsive-to-anti-vegf
The first-in-human trial of VRON-0200, a novel immunotherapy for chronic hepatitis B virus, presented at the APSAL meeting, demonstrates a promising safety and tolerability profile.
Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab...
https://www.hcplive.com/view/managing-a-treatment-experienced-patient-with-namd
Qazi discusses tofacitinib’s role in acute severe ulcerative colitis management as a potential first-line therapy to increase treatment responsiveness.
Dermatology experts highlight VISIBLE trial results when using guselkumab in patients with skin of color.
https://www.hcplive.com/view/results-of-visible-trial-in-patients-with-skin-of-color
Dr Linda Stein Gold, Dr Mona Shahriari and Dr Seemal Desai discuss VISIBLE trial, a randomized clinical trial specifically designed to examine treatment outcomes with guselkumab in patients with ...
https://www.hcplive.com/view/guselkumab-in-patients-with-skin-of-color-visible-trial-design
Findings from a novel study supports the JAK inhibitor tofacitinib as a potential first-line therapy for ASUC.
Qazi discusses a review of the BLUE-C trial and explains the rise of noninvasive CRC screening and surveillance options, but highlights the need for colonoscopy nonetheless.
As clinicians work to improve CRC screening rates, a promising new test has shown favorable accuracy in detecting cases.
Vadadustat tablets are now approved for the treatment of anemia due to CKD in adults who have been receiving dialysis for ≥ 3 months.
https://www.hcplive.com/view/fda-approves-vadadustat-vafseo-anemia-ckd-adult-patients-dialysis
At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline.
A new analysis summarized evidence on the effects of allogeneic HSCT on SCD-related organ dysfunction in pediatric and adult patients with SCD.
https://www.hcplive.com/view/allogenic-hsct-improve-sickle-cell-disease-related-organ-dysfunction
Mohamed Cherry, MD, and Neil Kramer, MD, shed light on a phase 1 trial using CAR-T cell therapy for SLE and its potential implications for lupus treatment.